Welcome to our dedicated page for ICU MEDICAL INC/DE SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ICU MEDICAL INC/DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ICU MEDICAL INC/DE's regulatory disclosures and financial reporting.
ICU Medical Inc/DE Chief Information Officer Ben Sousa reported a sale of 2,250 shares of common stock on 2026-08-12 in an open market or private transaction. The shares were sold at $178.3152 per share, leaving him with 3,076 shares of directly held common stock.
ICU Medical, Inc. is the subject of a Form 144 notice covering a proposed sale of 2,250 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, New York. The shares have an aggregate market value of $401,209.20 and are listed on NASDAQ. The filing also lists that these shares were acquired through equity compensation events, including restricted stock vesting and performance stock units in 2025 and 2026.
ICU Medical Inc. (ICUI) Chief Operating Officer Christian B. Voigtlander reported an open-market sale of 8,929 shares of common stock on 2026-08-11 at a weighted average price of $182.93 per share, with individual trade prices ranging from $182.85 to $183.03. Following this transaction, he directly owns 37,377 shares of ICU Medical common stock.
ICU Medical Inc. director Elisha W. Finney sold common shares, disposing of 378 shares of ICU Medical Inc. common stock on 2026-08-11 in an open market or private transaction at a weighted average price of $182.4818 per share. The trades occurred in a price range from $182.4808 to $182.5701. Following this transaction, Finney directly holds 4,871 common shares of ICU Medical Inc.
ICU Medical, Inc. (ICUI) has a planned resale of 8,929 shares of common stock, handled through Morgan Stanley Smith Barney LLC Executive Financial Services and listed on NASDAQ. The filing lists an aggregate market value of approximately $1,633,403.62 for these shares, compared with 25,007,038 shares of common stock outstanding. The shares relate to previously exercised options in May 2025 and equity awards (restricted stock and performance stock units) vesting on March 15, 2026, with an approximate sale date of August 11, 2026.
ICU Medical Inc. reports a planned sale of common stock by an affiliated holder under securities resale rules. The planned transaction covers 378 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.
The shares were originally acquired on May 13, 2020 as restricted stock vesting under a registered plan in consideration for services rendered. The filing lists an aggregate market value of $68,978.08 for the planned sale and shows 25,007,000 shares of common stock outstanding as context.
ICU Medical reported total revenues of $551,683 (in thousands) for the quarter ended June 30, 2026, slightly above the prior year, while cost of goods sold declined to $316,630 (in thousands). Gross profit increased to $235,053 (in thousands) and income from operations rose to $39,127 (in thousands), aided by $18,900 (in thousands) of tariff refunds recorded within tariffs and duties. Quarterly net income was $19,087 (in thousands), compared with $35,338 (in thousands) a year earlier, when results included a $41,823 (in thousands) gain on a business sale.
For the first six months of 2026, net income reached $49,219 (in thousands), helped by a $27,644 (in thousands) income tax benefit driven largely by releases of unrecognized tax benefits. Net cash provided by operating activities improved to $119,059 (in thousands), while cash and cash equivalents were $298,299 (in thousands) and long‑term debt was $1,212,449 (in thousands) as of June 30, 2026 after $54,688 (in thousands) of principal repayments. The company continued restructuring and integration of the Smiths Medical acquisition, incurring $38,103 (in thousands) in related expenses and recording $7,922 (in thousands) of non‑cash lease impairments, and it is recognizing equity income and service revenues from its 40% stake in the Otsuka ICU Medical IV Solutions joint venture.
ICU Medical reported second quarter 2026 results and raised its full‑year 2026 outlook. GAAP revenue for the quarter was $551.7 million, up 1% year over year, while non-GAAP organic revenue grew 6%. GAAP gross margin improved to 43% from 38%. GAAP net income was $19.1 million, or $0.76 per diluted share, compared with $35.3 million, or $1.43, a year earlier, which included a gain on sale of business. Adjusted diluted EPS rose to $2.37 from $2.10 and Adjusted EBITDA increased to $110.0 million from $100.3 million.
Consumables revenue grew to $289.3 million and Infusion Systems to $189.0 million, while Vital Care declined to $73.4 million following the 2025 IV Solutions divestiture. For fiscal 2026, the company now guides GAAP net income to $73–$83 million and GAAP EPS to $2.89–$3.29. Adjusted EBITDA guidance increased to $415–$435 million and adjusted EPS to $8.60–$9.00. As of June 30, 2026, cash and cash equivalents were $298.3 million, with total debt of about $1.23 billion and a net leverage ratio of 2.28x.
Form 144 notice reporting proposed sales of common-equity awards. The excerpt lists proposed disposals tied to equity compensation: 569 Performance Stock Units dated 02/15/2019, 282 Performance Stock Units dated 01/17/2020, and 1,272 restricted shares vesting under a registered plan dated 02/13/2020. The filing shows an administrative header with a dollar figure $280,684.80 and an entry 2,123 (context not fully detailed) dated 05/22/2026.
ICU Medical Inc. President Daniel Woolson reported an open-market sale of 2,123 shares of Common Stock. The shares were sold at a weighted average price of $132.2114 per share, with individual trade prices ranging from $132.03 to $132.33. After this transaction, Woolson directly holds 22,479 shares of ICU Medical common stock. The filing notes that detailed trade-by-trade pricing information is available upon request.